Recurrent Clostridioides difficile infection can be treated with fecal microbiota transplants. FDA approval of Seres Therapeutics’ Vowst makes it the first oral microbiome therapy.
Seres Therapeutics’ ambitions to treat ulcerative colitis with a microbiome drug were dealt a setback as its experimental therapy failed in Phase 2 testing. The company plans a “rigorous scientific analysis” to assess what happened and to determine the next steps for the program.
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
Companies that target the microbiome for various therapies have rallied $840 million since 2010, according to a new report by Silicon Valley Bank that analyzes the wider progress of the field.
Seres Therapeutics had a rough 2016, but it's optimistic that those hard-earned lessons could now help it succeed. Following discussions with FDA, it has moved into a pivotal Phase 3 trial in recurrent C. difficile infections.